Celsion to Present at Two Upcoming Healthcare Conferences in New York City

COLUMBIA, Md., Sept. 7 /PRNewswire/ -- Celsion Corporation (Nasdaq: CLSN) announced today that Michael H. Tardugno, Celsion's president and CEO, will present at the Rodman & Renshaw 12^th Annual Healthcare Conference on Tuesday, September 14 at 2:50 P.M. ET.  The conference is being held September 13 – 15, 2010 at the New York Palace Hotel in New York City.

Mr. Tardugno will also present at the Fifth Annual JMP Securities Healthcare Conference on Tuesday, September 28 at 3:00 P.M. ET.  The conference is being held September 27 – 28, 2010 at the New York Palace Hotel in New York City.

An audio webcast of both presentations will be available on Celsion's website at www.celsion.com.

About Celsion

Celsion is a leading oncology company dedicated to the development and commercialization of innovative cancer drugs including tumor-targeting treatments using focused heat energy in combination with its heat-activated drug delivery systems. Celsion lead product, ThermoDox®, is a proprietary heat-activated liposomal encapsulation of doxorubicin and is currently being evaluated under a Special Protocol Assessment (SPA) agreement with the U.S. Food and Drug Administration (FDA) in a 600 patient global Phase III trial in patients with non-resectable hepatocellular carcinoma (HCC), commonly referred to as primary liver cancer.  With nearly 70% of patients enrolled in the trial, Celsion is targeting to complete patient enrollment by year end 2010.  The FDA recently designated the Company's HEAT Study of its investigational drug, ThermoDox®, in combination with radiofrequency ablation (RFA), as a Fast Track Development Program.  Celsion has research, license, or commercialization agreements with leading institutions such as the National Institutes of Health, Duke University Medical Center, University of Hong Kong, Cleveland Clinic, and the North Shore Long Island Jewish Health System.

Celsion wishes to inform readers that forward-looking statements in this release are made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Readers are cautioned that such forward-looking statements involve risks and uncertainties including, without limitation, unforeseen changes in the course of research and development activities and in clinical trials by others; possible acquisitions of other technologies, assets or businesses; possible actions by customers, suppliers, competitors, regulatory authorities; and other risks detailed from time to time in the Company's periodic reports filed with the Securities and Exchange Commission.

SOURCE Celsion